Study highlights potential of genomic tests for early stage prostate cancer

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests – Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris – can help doctors make better decisions about how to treat patients with early stage prostate cancer.

EMA pins lack of long-term data as rationale for Novartis’ failed Vijoice bid – Pharmaceutical Technology

Share this article The European Medicines Agency (EMA) released a report detailing the reasons for the withdrawal of Novartis marketing authorisation application for Vijoice. Credit:

March 14, 2024

Pfizer ups 2024 guidance by $1B after multiple rounds of cost cuts

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Study highlights potential of genomic tests for early stage prostate cancer

EMA pins lack of long-term data as rationale for Novartis’ failed Vijoice bid – Pharmaceutical Technology

Pandemic-induced social isolation: Assessing its impact on older adults’ wellbeing

Pfizer ups 2024 guidance by $1B after multiple rounds of cost cuts

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe